June 2019 - Volume 3 - Issue - Contributor Index

Author:
Za, T.
Author:
Zabaleta, A.

SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES: S121

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3:12-13, June 2019.

DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM): PS1348

Pérez, C.; Botta, C.; Zabaleta, A.; More

HemaSphere. 3:615-616, June 2019.

OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM: PS1402

Peña, C.; Schutz, N. P.; Bove, V.; More

HemaSphere. 3:643-644, June 2019.

Author:
Zabalza, A.
Author:
Zabek, A.

EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA: PF524

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3:214-215, June 2019.

Author:
Zaccaria, G. M.

COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL: PS1248

Ferrero, S.; Zaccaria, G. M.; Barbero, D.; More

HemaSphere. 3:569-570, June 2019.

QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK: PS1312

Drandi, D.; Alcantara, M.; Barbero, D.; More

HemaSphere. 3:599, June 2019.

Author:
Zach, O.

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL: PS1331

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3:607-608, June 2019.

Author:
Zachee, P.
Author:
Zacheo, I.
Author:
Zackova, D.

DNA-BASED BCR-ABL1 ANALYSIS PROVIDES A “TRAFFIC LIGHT” STRATIFICATION MODEL FOR CHRONIC MYELOID LEUKEMIA WITH IMPLICATIONS FOR TREATMENT FREE REMISSION: PF414

Polakova, Machova K.; Zizkova, H.; Zuna, J.; More

HemaSphere. 3:159, June 2019.

Author:
Žácková, M.
Author:
Zafar, F.

HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT: PF631

Reece, D.; Bahlis, N. J.; Samaras, C.; More

HemaSphere. 3:268-269, June 2019.

Author:
Zagaria, A.
Author:
zaghloul, M.
Author:
Zagloul, N.
Author:
Zagotto, G.

TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL): PS1145

Pagano, M. A.; Tibaldi, E.; Brunati, A. M.; More

HemaSphere. 3:518-519, June 2019.

Author:
Zagozdzon, R.

EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA: PF524

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3:214-215, June 2019.

Author:
Zaharov, O.

INTERFERON-FREE ANTIVIRAL THERAPY IN THE TREATMENT OF RELAPSE HEPATITIS C VIRUS ASSOCIATED MARGINAL ZONE LYMPHOMA: PB2014

Lepkov, S.; Subortceva, I.; Tumian, G.; More

HemaSphere. 3:911, June 2019.

Author:
Zahra, M.
Author:
Zaidi, A.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Zaidi, M.
Author:
Zaitseva, G.
Author:
Zaja, F.

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL: S104

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3:3, June 2019.

ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP: PF695

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3:302, June 2019.

Author:
Zak, P.
Author:
Žák, P.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.

Author:
Zaka, A.

A MULTICENTRE, RANDOMIZED, NON-INFERIORITY TRIAL COMPARING THE EFFICACY OF DEFERIPRONE VERSUS DEFERASIROX IN PEDIATRIC PATIENTS AFFECTED BY TRANSFUSION-DEPENDENT HEMOGLOBINOPATHIES (DEEP-2 TRIAL): S144

Kattamis, A.; Felisi, M.; Reggiardo, G.; More

HemaSphere. 3:23-24, June 2019.

Author:
Zakharko, E.
Author:
Zakharov, S.
Author:
Zaki, I.
Author:
Zaki, M.

POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL: PF595

Dimopoulos, M.; Weisel, K.; Moreau, P.; More

HemaSphere. 3:250-251, June 2019.

Author:
Zaliova, M.

MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: PF176

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3:40-41, June 2019.

Author:
Zalyalov, Y.
Author:
Zalyalov, Y. R.
Author:
Zamagni, E.

A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS: PF560

Martello, M.; Termini, R.; Borsi, E.; More

HemaSphere. 3:232, June 2019.

CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS: S872

Gay, F.; Cerrato, C.; Scalabrini, Rota D.; More

HemaSphere. 3:390-391, June 2019.

UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA: PS1349

Mateos, M.-V.; Kumar, S.; Gonzalez, V.; More

HemaSphere. 3:616, June 2019.

Author:
Zambello, R.

SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY: PF586

Larocca, A.; Salvini, M.; Gaidano, G.; More

HemaSphere. 3:244, June 2019.

TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL): PS1145

Pagano, M. A.; Tibaldi, E.; Brunati, A. M.; More

HemaSphere. 3:518-519, June 2019.

Author:
Zambrano, W. J.
Author:
Zamò, A.

COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL: PS1248

Ferrero, S.; Zaccaria, G. M.; Barbero, D.; More

HemaSphere. 3:569-570, June 2019.

Author:
Zamora, L.
Author:
Zamora, R.
Author:
Zanabilli, J.
Author:
Zanaglio, C.

OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY: S882

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3:396-397, June 2019.

MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT): PS1540

Turra, A.; Polverelli, N.; Corvini, F.; More

HemaSphere. 3:711, June 2019.

Author:
Zanardi, S.
Author:
Zang, D. Y.
Author:
Zang, D.-Y.
Author:
Zangari, M.
Author:
Zanghì, P.

PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE: PF227

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3:65-66, June 2019.

Author:
Zanni, M.

PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL): S1597

Balzarotti, M.; Spina, M.; Monagheddu, C.; More

HemaSphere. 3:735, June 2019.

Author:
Zanotti, R.

SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS: PS1437

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3:662-663, June 2019.

FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES: PS1461

Tanasi, I.; Bonifacio, M.; Pizzolato, M.; More

HemaSphere. 3:673, June 2019.

Author:
Zanwar, S.
Author:
Zapata, N.

SURVIVAL ANALYSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH INTENSIVE CHEMOTHERAPY: RESULTS OF A MEXICAN NATIONAL AML REGISTRY.: PB1739

Demichelis, R.; Zapata, N.; Leyto, F.; More

HemaSphere. 3:800, June 2019.

OVERAL SURVIVAL OF MEXICAN NATIONAL REGISTRY OF ACUTE PROMYEOLOCYTIC LEUKEMIA, AN ANALYSIS OF 324 CASES: PB1773

Zapata, N.; Montaño, E.; Ramos, C.; More

HemaSphere. 3:814, June 2019.

Author:
Zapico, E.
Author:
Zappasodi, P.

A BAL-DRIVEN ANTIMICROBIAL TREATMENT IMPROVES CLINICAL OUTCOME IN HEMATOLOGIC MALIGNANCIES PATIENTS WITH LUNG INFILTRATES DETECTION: A PROSPECTIVE MULTICENTER STUDY OF THE SEIFEM GROUP: S1637

Marchesi, F.; Cattaneo, C.; Criscuolo, M.; More

HemaSphere. 3:756-757, June 2019.

Author:
Zappasoldi, P.

NELARABINE AS SALVAGE THERAPY AND BRIDGE TO ALLOGENEIC STEM CELLS TRANSPLANTATION IN 118 ADULT PATIENTS WITH RELAPSED/REFRACTORY T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA. A CAMPUS-ALL, PHASE 4, STUDY.: S1620

Candoni, A.; Lazzarotto, D.; Curti, A.; More

HemaSphere. 3:748, June 2019.

Author:
Zapreeva, I.
Author:
Zaragoza, A.

SURVIVAL ANALYSIS OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH INTENSIVE CHEMOTHERAPY: RESULTS OF A MEXICAN NATIONAL AML REGISTRY.: PB1739

Demichelis, R.; Zapata, N.; Leyto, F.; More

HemaSphere. 3:800, June 2019.

Author:
Zarina, S.
Author:
Zaritskey, A.
Author:
Zarubina, K.
Show: